Vein Specialist Antonios Gasparis Joins Northwell Health

Antonios Gasparis, MD

Renowned vascular surgeon/vein specialist Antonios Gasparis, MD, has joined Northwell Health as the new System Chief for Venous Disease. Known for developing world-class vein programs, Dr. Gasparis looks to increase access to care and expand treatment options to patients across the health system, bringing this level of care close to home. He comes to Northwell from Stony Brook University Hospital.

Career

Over his career, Dr. Antonios Gasparis has published and presented on hundreds of topics and received numerous academic honors and awards for his research. He has served as president of the American Venous Forum – the leading international society in venous and lymphatic disease – and founded and co-directed several educational programs including the Venous Symposium, one of the world’s largest venous meetings.

Northwell CEO Said

“I’m honored to welcome Dr. Antonios Gasparis to the Northwell Health family,” said Michael Dowling, Northwell’s president and CEO. “Dr. Gasparis has decades of unparalleled experience in the field of venous disease and we’re so excited for him to bring that knowledge to Northwell. Working together, we’ll be able to treat more patients across the state with this condition and bring a better quality of life to these patients than ever before.”

Vein disease is common across the country, affecting about 40 percent of the population. Dr. Gasparis will work to develop vein centers across Northwell’s multiple hospitals and satellite locations. He will also be standardizing venous treatments across Northwell and increasing patient access to treatment for venous disease.

Dr. Gasparis, with his extensive experience with new technology, will be able to bring cutting-edge, minimally invasive procedures to Northwell. Northwell is about to be one of two centers in the United States and the first in New York to participate in a clinical trial that will use high-intensity focused ultrasound, known as HIFU, to treat varicose veins. The treatment will allow patients to receive completely non-invasive varicose vein treatment for the first time.

To Create a Venous Program

“Creating a venous program like this, at the scale that Northwell provides, is something I’ve wanted to do for at least a decade,” said Dr. Antonios Gasparis. “I’m really blessed that I can make a difference for people suffering from venous disease. Venous disease encompasses a range of conditions that can be debilitating. We’re building a program that tackles them all, from the most common to the most complex.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”